Journal article
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy
S Lunke, A El-Osta
Neurotherapeutics | SPRINGER | Published : 2013
Abstract
Spinal muscular atrophy (SMA), a neurodegenerative disease with potentially devastating and even deadly effects on affected individuals, was first described in the late nineteenth century. Although the survival of motor neuron (SMN) gene was identified nearly 2 decades ago to be causative of the disease, neither an effective treatment nor a cure are currently available. Yet efforts are on-going to test a multitude of treatment strategies with the potential to alleviate disease symptoms in human and clinical trials. Among the most studied compounds for the treatment of SMA are histone deacetylase inhibitors. Several of these epigenetic modifiers have been shown to increase expression of the c..
View full abstractGrants
Funding Acknowledgements
The authors acknowledge grant and fellowship support from the National Health and Medical Research Council (NHMRC) and the National Heart Foundation of Australia (NHF). S. L. was awarded a Monash Graduate Scholarship and A.E-O. is NHMRC Senior Research Fellows. Supported in part by the Victorian Government's Operational Infrastructure Support program.